Related Experiment Videos
Topical therapies and medications in the pediatric patient
1Department of Dermatology, University of Texas Medical School at Houston, USA. dmetry@utmmg.med.uth.tmc.edu
Insights
Pediatric topical therapy requires careful consideration of absorption and toxicity risks unique to children. Individualized treatment plans and new drug research are crucial for effective and safe management of pediatric skin conditions.
Area of Science:
- Pediatric Dermatology
- Pharmacology
- Drug Safety
Background:
- Topical medications are essential for treating pediatric skin diseases.
- Infants and children have unique percutaneous absorption rates and toxicity risks with topical drugs.
- Individualized topical therapy, considering vehicle, application, and cost, is key to success.
Purpose of the Study:
- To highlight the unique considerations for topical medication use in pediatric patients.
- To emphasize the importance of individualized treatment and ongoing drug research.
- To introduce emerging therapies with potential for improved efficacy and safety.
Main Methods:
- Review of current literature on pediatric topical therapy.
- Analysis of factors influencing percutaneous absorption and toxicity in children.
- Discussion of regulatory changes and their impact on pediatric drug development.
Main Results:
- Physicians must be aware of age-specific differences in topical drug absorption and toxicity.
- Commercial topical therapies often lack FDA approval for pediatric use.
- Recent legislation aims to boost pediatric drug research, with new agents like tacrolimus showing promise.
Conclusions:
- Effective pediatric topical therapy necessitates individualized approaches.
- Further research and development of pediatric-specific topical treatments are vital.
- Emerging therapies may offer safer and more effective options for children's skin conditions.
Abstract:
Topical medications and therapies are necessary for the proper management of skin diseases in children; however, physicians must be aware of the differences in percutaneous absorption and the risks for toxicity from topical medications, which are often unique to infants and children. Topical therapy must be individualized, and success often depends on proper vehicle selection, ease of application, and cost to patients and their families. Although many commercially available topical therapies are not FDA approved for use in children, recently enacted legislation has served to stimulate much-needed drug research in pediatric patients. New therapies on the horizon, such as tacrolimus, may prove to be equally efficacious and less toxic.